Table 2.
Xanthine oxidase inhibitory properties of LPPC and its metabolites.
| Compounds | Inhibition (%) at 200 μg/ml | IC50 (μg/ml) |
|---|---|---|
| LPPC | 64.67 ± 1.62e | 79.77 ± 1.80e |
| (-)-Epicatechin | 78.63 ± 1.72b | 58.43 ± 1.86b |
| A-type dimer | 71.37 ± 2.32c | 68.37 ± 3.50c |
| A-type trimer | 67.80 ± 0.40d | 74.87 ± 1.30d |
| 3-Hydroxyphenylacetic acid | 21.13 ± 1.78k | >200 |
| 3-Hydroxyphenylpropionic acid | 27.03 ± 1.44ij | >200 |
| 4-Hydroxyphenylpropionic acid | 29.43 ± 0.75i | >200 |
| Vanillic acid | 25.03 ± 1.47j | >200 |
| Shikimic acid | 61.13 ± 0.81f | 96.17 ± 1.64f |
| Caffeic acid | 60.67 ± 2.16f | 95.67 ± 3.82f |
| p-Coumaric acid | 57.40 ± 0.62g | 139.90 ± 5.80g |
| m-Coumaric acid | 52.80 ± 1.57h | 154.57 ± 5.70h |
| Allopurinol | 85.60 ± 3.13a | 5.63 ± 0.45a |
The means in the same column sharing a different letter were significantly different (P < 0.05) between the groups.